The anti‑CD38 IgG4–IFN‑α2b fusion binds CD38 on target cells and delivers IFN‑α locally; IFN‑α engages IFNAR on the same cell, activating type I interferon signaling that induces antiproliferative/apoptotic programs, killing CD38+ cells (with additional immune stimulation as a secondary effect).